Group 1 - The biopharmaceutical sector experienced a decline of 0.64% on September 3, with Sai Sheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] - Notable gainers in the biopharmaceutical sector included Baipu Sais, which rose by 12.10% to a closing price of 65.50, and Yuan Yang Crystal Sea, which increased by 9.14% to 32.95 [1] Group 2 - The net capital outflow from the biopharmaceutical sector was 446 million yuan, while retail investors saw a net inflow of 292 million yuan [3] - The table of individual stock capital flows indicates varying levels of investment activity among different companies within the sector [3]

山东未名生物医药股份有限公司 董事会薪酬与考核委员会关于公司 2025 年股票期权 激励计划相关事项的核查意见 （五）中国证监会认定的其他情形。公司具备实施股权激励计划的主体资格。 二、公司本激励计划所确定的激励对象不存在《管理办法》第八条规定的不 得成为激励对象的以下情形： （一）最近 12 个月内被证券交易所认定为不适当人选； （二）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （三）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； 山东未名生物医药股份有限公司（以下简称"公司"）董事会薪酬与考核委 员会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《深圳证券交易所股票上市规则》（以下简称 "《上市规则》"）、《山东未名生物医药股份有限公司章程》（以下简称"《公 司章程》"）的规定，对《山东未名生物医药股份有限公司 2025 年股票期权激 励计划（草案）》（以下简称"本激励计划"）及其他相关资料进行审核，发表 核查意见如下： ...

证券代码：002581 证券简称：ST未名 公告编号：2025-065 山东未名生物医药股份有限公司 山东未名生物医药股份有限公司(以下简称"公司")第六届董事会第六次会 议于 2025 年 8 月 29 日上午 10 时以通讯方式召开。应参加表决董事 11 名，实际 参加表决董事 11 人，分别为：岳家霖、刘文俊、徐隽雄、周婷、陈星、史晓如、 黄桂源、蔡艳红、张荣富、刘洋、夏阳。董事会会议通知已于 2025 年 8 月 27 日以通讯方式发出，会议由公司董事长岳家霖先生主持。本次董事会的召集和召 开符合国家有关法律法规、《董事会议事规则》及《公司章程》的规定。本次会 议审议了如下议案： 二、董事会会议审议情况 （一）审议通过了《关于〈山东未名生物医药股份有限公司 2025 年股票期权 激励计划（草案）〉及其摘要的议案》 为进一步完善公司治理结构，建立、健全公司长期激励与约束机制，倡导公 司与管理层及骨干员工共同持续发展的理念，充分调动董事、高级管理人员、中 层管理人员及核心骨干员工的积极性，有效地将股东利益、公司利益和员工个人 利益结合在一起，提升公司的核心竞争力，确保公司发展战略和经营目标的实现， 公司依 ...

Core Viewpoint - Shandong Weiming Biological Pharmaceutical Co., Ltd. has proposed a stock option incentive plan for 2025, aiming to enhance corporate governance and align the interests of shareholders, the company, and employees [1][8]. Summary by Sections Incentive Plan Overview - The 2025 stock option incentive plan involves granting a total of 46 million stock options, representing 6.97% of the company's total share capital of 659,735,586 shares [2][13]. - The plan is designed to motivate 154 individuals, including directors, senior management, and key technical/business personnel, excluding independent directors [2][11]. Stock Option Details - Each stock option allows the purchase of one share at a price of 7.39 RMB, with adjustments possible in case of capital changes [2][18]. - The plan's validity extends up to 44 months from the date of authorization [3][7]. Conditions for Implementation - The plan requires approval from the shareholders' meeting and must be executed within 60 days post-approval [5][33]. - The company commits not to provide loans or guarantees for any participant in the incentive plan [4][11]. Performance Assessment - The performance assessment for the stock options will be based on company-level and individual-level criteria, with specific growth targets set for revenue and net profit [20][21]. - The company aims for a revenue growth rate of at least 5% for the first exercise period and 10% for the second [20][21]. Adjustments and Accounting - Adjustments to the number of stock options and exercise prices will be made in response to corporate actions such as stock splits or dividends [25][26]. - The fair value of the stock options will be calculated using the Black-Scholes model, with specific parameters outlined for valuation [27][28]. Financial Impact - The implementation of the incentive plan is expected to affect the company's future net profit and return on equity, with estimated costs associated with the stock options detailed [29][30].

Core Points - The company, Shandong Weiming Bio-Pharmaceutical Co., Ltd., has proposed a stock option incentive plan for 2025, aiming to enhance corporate governance and align the interests of shareholders, the company, and employees [8][36]. - The plan involves granting a total of 46 million stock options, representing 6.97% of the company's total share capital, with a one-time grant and no reserved rights [2][13]. - The exercise price for the stock options is set at 7.39 RMB per share, with adjustments possible based on corporate actions such as stock dividends or capital increases [5][17]. Summary by Sections Plan Overview - The stock option incentive plan is established in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][8]. - The plan is designed to motivate 154 individuals, including directors, senior management, and key technical/business personnel, excluding independent directors [4][11]. Stock Options Details - The total number of stock options granted is 46 million, which does not exceed 10% of the company's total share capital [2][13]. - Each stock option grants the right to purchase one share of the company's A-shares at the specified exercise price [2][13]. Duration and Conditions - The effective period of the incentive plan is up to 44 months from the date of stock option authorization [3][6]. - The plan includes specific conditions under which stock options can be granted and exercised, ensuring compliance with regulatory requirements [19][20]. Performance Assessment - The performance assessment for the stock options is based on company-level and individual-level criteria, with specific growth targets set for revenue and net profit [21][22]. - The company aims for a net profit growth rate of at least 10% for the second exercise period, ensuring that performance metrics are aligned with shareholder interests [21][24]. Adjustments and Accounting - The plan outlines methods for adjusting the number of stock options and exercise prices in response to corporate actions [26][27]. - The company will use the Black-Scholes model to calculate the fair value of the stock options for accounting purposes [29][30].

Overall Distribution - The company plans to grant a total of 4,600,000 stock options to middle management and core technical personnel, which represents 6.97% of the total stock options granted under the incentive plan [1] - No individual recipient will receive more than 1.00% of the company's total share capital through the stock incentive plan during its effective period [1] - The total number of shares involved in all effective stock incentive plans will not exceed 10.00% of the company's total share capital [1] Adjustment Mechanism - If any recipient voluntarily waives their granted rights for personal reasons, the board of directors will adjust the number of shares granted accordingly, either by directly reducing the waived shares or redistributing them among other recipients [1]

Core Viewpoint - The company has established a stock option incentive plan for 2025 to enhance its governance structure and align the interests of shareholders, management, and employees, aiming for steady performance improvement and strategic goal achievement [1]. Group 1: Assessment Objectives - The assessment aims to improve the company's governance structure and establish a long-term incentive mechanism, promoting a shared development philosophy among the company, management, and key employees [1]. - The plan is designed to motivate management and core personnel to enhance the company's core competitiveness and ensure the achievement of development strategies and operational goals [1]. Group 2: Assessment Principles - The evaluation must adhere to principles of fairness, openness, and justice, closely linking the stock option incentive plan with the performance and contributions of the incentivized individuals [2]. Group 3: Assessment Scope - The assessment applies to all individuals identified in the stock option incentive plan [2]. Group 4: Assessment Indicators and Standards - The exercise of stock options is contingent upon meeting performance targets at both the company and individual levels, with specific performance goals set for two exercise periods [2]. - For the first exercise period, the company must achieve either a growth rate of no less than 5% or a profit growth rate of no less than 10% [2]. - For the second exercise period, the company must achieve either a growth rate of no less than 10% or a profit growth rate of no less than 15% [2]. Group 5: Assessment Procedures - The Human Resources Department, under the guidance of the Board's Compensation and Assessment Committee, is responsible for the assessment work and maintaining assessment results [4]. - The assessment process includes setting KPIs for each organizational level and signing performance contracts, with evaluations conducted by higher-level management [4]. Group 6: Assessment Result Management - The Human Resources Center submits performance assessment reports to the Compensation and Assessment Committee for review, with results communicated to the incentivized individuals within five working days [5]. - Individuals can appeal assessment results within five days of feedback, and the Human Resources Center may re-evaluate if there are reasonable grounds for reconsideration [5].

Compliance Requirements - The financial report for the most recent accounting year must not have received a negative opinion or inability to express an opinion from the registered accountant [2] - Internal controls for the most recent accounting year must not have received a negative opinion or inability to express an opinion from the registered accountant [2] - There should be no instances of profit distribution not complying with laws, regulations, or company articles within the last 36 months [2] - No loans or financial assistance should be provided to incentive objects [2] Incentive Object Compliance - Incentive objects must not include shareholders or actual controllers holding more than 5% of the company's shares [2] - No inappropriate designations by the stock exchange or the China Securities Regulatory Commission (CSRC) in the last 12 months [2] - No major legal violations leading to administrative penalties or market entry bans by the CSRC in the last 12 months [2] - Compliance with the Company Law regarding eligibility to serve as directors or senior management [2] Incentive Plan Compliance - The total number of shares involved in all effective stock incentive plans must not exceed 10% of the company's total equity [2] - Individual incentive objects must not receive more than 1% of the company's total equity through all effective stock incentive plans [2] - The reserved rights ratio for incentive objects must not exceed 20% of the total rights to be granted in the current stock incentive plan [2] - Performance assessment indicators must be established for directors and senior management as conditions for exercising rights [2] Disclosure Requirements - The stock incentive plan must detail compliance with the Stock Incentive Management Measures and any potential issues with stock distribution [3] - The purpose of the stock incentive plan and the basis for determining incentive objects must be clearly stated [3] - The number of rights to be granted, types of stocks involved, and their proportion to the company's total equity must be disclosed [5] - The plan must include the effective period, pricing methods, and conditions for exercising rights [5][6] Performance Assessment and Compliance - Performance assessment indicators must be objective, clear, and conducive to enhancing the company's competitiveness [6] - The interval between the grant date of restricted stocks and the first release date must not be less than 12 months [6] - The company must ensure that the stock incentive plan does not harm the interests of the company and all shareholders [7]

近日，公司已向中国证券登记结算有限责任公司深圳分公司提交注销上述股 票期权的申请。截至本公告披露日，经中国证券登记结算有限责任公司深圳分公 司审核确认，公司已完成上述合计 46,332,882 份股票期权的注销事宜。 山东未名生物医药股份有限公司 关于 2023 年股票期权激励计划部分股票期权 注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开了第五届董事会第三十六次会议、第五届监事会第二十三次会议、第五届 董事会薪酬与考核委员会第九次会议，审议通过了《关于 2023 年股票期权激励 计划第二个行权期行权条件未成就及注销部分股票期权的议案》，因公司层面业 绩考核目标未成就及部分激励对象离职，公司本次拟对 2023 年股票期权激励计 划第二个行权期及对应离职注销人员合计 29,715,486 份股票期权进行注销。具 体内容详见公司于 2025 年 4 月 29 日在巨潮资讯网（www.cninfo.com.cn）披露 的《关于 2023 年股票期权激励计划第二个行 ...

截至发稿，ST未名市值为48亿元。 每经头条（nbdtoutiao）——近120个品牌、1600辆车逐鹿西南！下半年国内首个A级车展开幕：新能 源"第三极"将改写车市格局 （记者 胡玲） 每经AI快讯，ST未名（SZ 002581，收盘价：7.29元）8月29日晚间发布公告称，公司第六届第六次董事 会会议于2025年8月29日以通讯方式召开。会议审议了《关于〈山东未名生物医药股份有限公司2025年 股票期权激励计划（草案）〉及其摘要的议案》等文件。 2025年1至6月份，ST未名的营业收入构成为：制药业务分部占比100.0%。 ...